8-K: Myomo Unveils Ambitious 2028 Financial Targets and Strategic Growth Plan at Investor Day

Myomo, Inc. hosted an Investor & Analyst Day to detail its business model, long-term financial aspirations, and product roadmap, targeting $100 million in annual revenue by 2028.

Summary

• Myomo, Inc. hosted an Investor & Analyst Day on June 18, 2025, providing an in-depth review of its business model and long-range aspirational financial metrics.
• Lead generation has recovered from challenges faced early in the first quarter of 2025.
• Management believes the MyoPro patient population is largely untapped and advertising has not reached saturation.
• Approximately half of new pipeline additions originate from leads generated one year or more ago.
• Efforts to improve Medicare Advantage reimbursement are showing increasing success in winning patient appeals.
• More than 27 million lives are covered by private payer contracts that are either executed or in the process of execution.
• The company plans to increase manufacturing capacity, with existing space plus new space available in July 2025, sufficient to produce 250 MyoPros per month.
• Cost reduction projects are expected to generate approximately 200 basis points of gross margin improvement on a quarterly basis by the end of 2026.
• Myomo presented a long-range financial model with a goal of $100 million in annual revenue by 2028.
• Key elements of the aspirational model for 2028 include $15 million in annual International revenue and $20 million in annual O&P channel revenue.
• The company targets gross margins in the range of 70% to 72% and EBITDA margins in the range of 15% to 20%.
• Cash flow breakeven is projected at quarterly revenue of $17 million to $18 million.

Sentiment

Score: 8

Explanation: The document presents a highly positive and ambitious outlook, detailing strategic plans for significant growth, improved profitability, and expanded market penetration. While the targets are aspirational and risks are acknowledged, the overall tone and content are optimistic about future performance and market opportunity.

Positives

• Lead generation has recovered from early Q1 2025 challenges, indicating improved market outreach effectiveness.
• Management identifies a largely untapped population of prospective MyoPro patients, suggesting significant growth potential.
• Increasing success in winning Medicare Advantage reimbursement appeals improves patient access and revenue certainty.
• Over 27 million lives are covered by private payer contracts, expanding market reach and reimbursement opportunities.
• Manufacturing capacity is set to increase to 250 MyoPros per month, supported by new space available in July, enabling higher production volumes.
• Cost reduction projects are expected to yield approximately 200 basis points of quarterly gross margin improvement by the end of 2026.
• Ambitious long-range financial goals include $100 million in annual revenue by 2028, with strong gross margin (70-72%) and EBITDA margin (15-20%) targets.
• The company plans a roadmap for product enhancements and new product introductions, indicating continued innovation.

Negatives

• The financial targets presented are aspirational and forward-looking, not guaranteed outcomes.
• The company's dependence on external financing is noted as a risk if cash flow breakeven is not achieved or maintained.

Risks

• Ability to obtain sufficient reimbursement from third-party payers for products.
• Revenue concentration with Medicare and a particular insurance payer.
• Ability to continue normal operations and patient interactions without supply chain disruption.
• Effectiveness of marketing and commercialization efforts.
• Dependence upon external sources for financing if cash flow breakeven is not achieved or maintained.
• Ability to obtain and maintain strategic collaborations and realize intended results.
• Ability to effectively execute the business plan and scale up operations.
• Ability to remediate material weakness in internal control over financial reporting.
• Expectations as to product development programs, including improving existing products and developing new products.
• Ability to maintain and grow reputation and achieve market acceptance of products.
• Expectations as to clinical research program and clinical results.
• Ability to maintain adequate protection of intellectual property and avoid violation of others' intellectual property rights.
• Ability to gain and maintain regulatory approvals.
• Ability to compete and succeed in a highly competitive and evolving industry.
• General market, economic, environmental, and social factors that may affect the evaluation, fitting, delivery, and sale of products to patients.

Future Outlook

Myomo aims for significant growth, targeting $100 million in annual revenue by 2028, driven by international expansion and growth in the O&P channel. The company anticipates improving gross margins to 70-72% and EBITDA margins to 15-20%, with cash flow breakeven at $17-18 million in quarterly revenue. They also plan continuous product enhancements, new product introductions, and increased manufacturing capacity to support these goals.

Management Comments

• "Management believes that the population of prospective MyoPro patients remains largely untapped, and that the Company is not reaching a saturation point with its advertising."
• "Management will review efforts to improve Medicare Advantage reimbursement, including increasing success at winning appeals on behalf of patients."
• "Management will share that more than 27 million lives are covered by private payer contracts that have been executed or are in the process of being executed."
• "Management will discuss plans to increase manufacturing capacity, highlighting that existing manufacturing space plus new space expected to become available in July is sufficient to produce 250 MyoPros per month."
• "Management will review projects to reduce cost of goods that are expected to generate approximately 200 basis points of gross margin improvement on a quarterly basis by the end of 2026."

Industry Context

Myomo operates in the specialized and growing field of wearable medical robotics, specifically targeting individuals with neurological disorders and upper-limb paralysis. The company's MyoPro product line, which utilizes EMG signals to restore arm and hand function, positions it uniquely as it claims to be the only marketed device in the U.S. with this specific capability for daily living activities. The company's focus on expanding private payer contracts and improving Medicare Advantage reimbursement reflects the critical importance of navigating complex healthcare reimbursement landscapes to increase market penetration and patient access in the medical device industry.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess Myomo's performance against global industry benchmarks. The focus is on internal aspirational targets and strategic initiatives.

Stakeholder Impact

• Shareholders: Potential for significant value creation if the ambitious aspirational financial targets are met, indicating strong future growth and profitability.
• Patients: Improved access to MyoPro devices through increased private payer coverage (over 27 million lives) and higher success rates in Medicare Advantage appeals, potentially leading to enhanced quality of life and independence.
• Employees: Potential for company growth and expansion, which could lead to increased job opportunities and stability.
• O&P Providers: Opportunities for collaboration and partnership to provide MyoPro to their patients, expanding their service offerings.

Next Steps

• Continue efforts to improve Medicare Advantage reimbursement and increase success in winning patient appeals.
• Utilize new manufacturing space becoming available in July to increase production capacity to 250 MyoPros per month.
• Implement cost reduction projects to achieve approximately 200 basis points of gross margin improvement quarterly by the end of 2026.
• Execute on the roadmap for product enhancements, new product introductions, and sustaining engineering projects.
• Work towards achieving the long-range financial model goals for 2028, including $100 million in annual revenue and targeted margins.

Key Dates

Recommendation

Keywords

Myomo, MyoPro, wearable medical robotics, neurological disorders, upper-limb paralysis, orthosis, stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, neuromuscular disease, EMG signals, medical device, rehabilitation, investor day, financial targets, revenue growth, gross margin, EBITDA, manufacturing capacity, Medicare Advantage, O&P providers, telehealth evaluation